MLN8054

DB13061InvestigationalSmall molecule

MLN8054 has been used in trials studying the treatment of Colon Neoplasm, Breast Neoplasm, Bladder Neoplasm, Pancreatic Neoplasm, and Advanced Malignancies.

Mechanism: MLN8054 is a selective small-molecule Aurora A kinase inhibitor that has entered Phase I clinical trials for advanced solid tumors. MLN8054 inhibits recombinant Aurora A kinase activity in vitro and is selective for Aurora A over the family member Aurora B in cultured cells. MLN8054 treatment results in G2/M accumulation and spindle defects and inhibits proliferation in multiple cultured human tumor cells lines.
Curator reviewed
Formula / weight: C₂₅H₁₅ClF₂N₄O₂ · 476.862 g/mol (avg)
Code names: MLN-8054

Resolves to

Compound

UNIIBX854EHD63CAS869363-13-3ChEMBLCHEMBL259084ChEBI91366PubChem11712649

Structure

InChIKeyHHFBDROWDBDFBR-UHFFFAOYSA-NSMILESOC(=O)C1=CC=C(NC2=NC=C3CN=C(C4=C(C=CC(Cl)=C4)C3=N2)C2=C(F)C=CC=C2F)C=C1

Targets

O14965AURKA

What you can answer from here — as of August 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with MLN8054, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account